2013 Global Summit on Regulatory Science (GSRS13)Topic: Nanotechnology
Dates: September 11-12, 2013
Location: Little Rock, Arkansas
Current Highlight from March 29, 2013
Heterogeneity of KRAS Genes in Colon and Lung Tumors Complicates Personalized Medicine Treatments
NCTR scientists have published a Special Report in Personalized Medicine summarizing the evidence that undetected KRAS mutant subpopulations in tumors are subverting the efficacy of therapies targeting the epidermal growth factor receptor (EGFR). Although clinical studies have shown that the presence of KRAS mutations can predict failure of EGFR-targeted therapies, significant percentages of patients with wild-type KRAS tumors (no mutation detected) also fail to respond to these therapies. Frequently, colon and lung tumors contain KRAS mutant tumor subpopulations not detected by DNA sequencing and could account for the reduced efficacy. Since tumors frequently develop from more than one group of cells, novel preclinical models need to capture this complexity when evaluating and prioritizing combination therapies for subsequent clinical investigation.
For additional information, please contact Meagan Myers, Ph.D., or Barbara Parsons, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR.